Dignitana (DIGN) Q4 2024 earnings summary

Executive summary

• Achieved record high sales in Q4 2024, with net sales of 24.0 MSEK, up 13% year-over-year; full-year net sales reached 89.8 MSEK, a 4% increase over 2023.

• Transformation efforts led to improved profitability, with positive EBITDA in Q3 and Q4 despite substantial one-time operating expenses in Q2.

• Strategic expansion in key markets outside the U.S., including new distribution agreements in Europe, South America, and Asia.

• U.S. market poised for growth with new reimbursement standards and insurance legislation effective 2026.

Financial highlights

• Q4 2024 net sales: 24.0 MSEK (21.3), up 13% year-over-year; operating result: -1.6 MSEK (-3.7); net result: -1.1 MSEK (-4.9); EBITDA: 1.1 MSEK (0.1); EPS: -0.01 SEK (-0.07).

• Full-year 2024 net sales: 89.8 MSEK (86.1), up 4%; operating result: -18.3 MSEK (-15.0); net result: -19.1 MSEK (-17.2); EBITDA: -4.9 MSEK (0.1); EPS: -0.25 SEK (-0.25).

• Cash balance at year-end: 3.0 MSEK (6.0); average daily treatment revenue (ADTR) in Q4: 251 TSEK (238).

• Q4 cash flow from operating activities: 1.1 MSEK (-0.5); full-year: 0.4 MSEK (-5.7).

• Capex for 2024: 4.5 MSEK (3.8).

Outlook and guidance

• New U.S. reimbursement standards and New York insurance legislation effective 2026 expected to drive utilization and adoption.

• Ongoing transformation and cost control measures to support future profitability and scalability.

• Board and management believe current business plans and available credit facilities are sufficient for working capital needs over the next 12 months.